Results 161 to 170 of about 164,503 (308)
How to define severity: A review of allergic reaction severity scoring systems. [PDF]
Shah A, Dribin TE, Wang J.
europepmc +1 more source
Cumulative Antigen Suppression Reduces Clonal Plasma Cell Evolution in Gaucher Disease
ABSTRACT Chronic antigenic stimulation is implicated in the pathogenesis of monoclonal gammopathy and multiple myeloma, yet longitudinal human evidence linking sustained antigen exposure to modifiable clonal plasma cell evolution remains limited. Gaucher disease (GD), caused by biallelic GBA1 pathogenic variants, is characterized by accumulation of ...
Noor Ul Ain +10 more
wiley +1 more source
Case Report: Case of severe allergic reaction in a child caused by chlorhexidine skin disinfectant. [PDF]
Zhao Y +4 more
europepmc +1 more source
ABSTRACT Background The indication for nasal irrigation with corticosteroids after sinus surgery in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is well established, as surgery facilitates distribution throughout the sinonasal cavity.
Juliana Sant'Ana +5 more
wiley +1 more source
Allergic reaction to nalbuphine administration in a pre-adolescent patient: a case report and literature review. [PDF]
Li S.
europepmc +1 more source
Allergic reactions to carboplatin
A M, Hendrick, D, Simmons, B M, Cantwell
openaire +2 more sources
ABSTRACT Background Although shifts in nasal microbiota have been well‐documented in inflammatory upper airway conditions, microbiota tumor‐associated alterations remain uncharacterized. This study is the first to compare sinonasal microbiota profiles of patients with malignant tumors (MT), benign tumors (BT), and controls, offering insights into tumor‐
Evan A. Patel +13 more
wiley +1 more source
Allergic Reaction to Titanium Alloy Osteosynthesis Implants: A Case Report of Three Patients. [PDF]
Chou H +4 more
europepmc +1 more source
Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion +15 more
wiley +1 more source

